# IKEMA (NCT03275285)

> Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03275285
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Sanofi
- Conditions: Plasma Cell Myeloma
- Interventions: isatuximab SAR650984; carfilzomib; dexamethasone
- Enrollment: 302
- Primary outcome: Progression Free Survival (PFS) As Determined by Independent Response Committee (IRC): Primary Analysis
- Primary outcome: Progression Free Survival as Determined by Independent Response Committee: [Event Censored if Occurred >8 Weeks From Last Disease Assessment]: Primary Analysis
- Primary outcome: Progression Free Survival as Determined by Independent Response Committee: Final Analysis
- Primary outcome: Progression Free Survival as Determined by Independent Response Committee [Event Censored if Occurred >8 Weeks From Last Disease Assessment]: Final Analysis

## Commentary we found

- YouTube: 50
- Podcasts: 30
- X threads: 17

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=ikema-nct03275285

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03275285", "email": "<work email>"}; the inbox owner confirms by the emailed link.